We are developing new veterinary therapies, aided by advances in biotechnology including our proprietary PETization platform technology, which is designed to rapidly translate therapeutic monoclonal antibodies (mAbs) between species.
mAbs are a type of biologic therapy, a class of drug that has transformed human medicine in recent decades. Various challenges have previously impeded the introduction of mAbs as a successful class of therapies in veterinary medicine. At least two of our therapies in development are mAbs.
We invite you to watch the video above as an introduction to the principles underpinning much of our work.
If you would like to read more detail about the science involved, please read more about PETization and biologics at their respective pages, and register to receive news about educational opportunities.